LB Pharmaceuticals and Celldex Therapeutics Appoint Chief Commercial Officers to Accelerate New Drug Launches

Nov 15, 2025 19:33 CST Updated 19:33

LB Pharma

Antipsychotic Drug Developer

Celldex Therapeutics

Biopharmaceutical Manufacturer

Johnson & Johnson

Medical Device R&D and Manufacturer

Decans

Developer of High-Performance Orthopedic Implants and Surgical Technique Systems

Abstract:LB Pharma and Celldex Therapeutics Announce Appointment of Chief Commercial Officers (CCOs) to Accelerate Launch Preparation for Key New Drugs

LB Pharma Leverages IPO Funds to Build Team for Psychiatric Drug Development

New York-based biopharmaceutical company LB Pharma, which recently raised $285 million through its Initial Public Offering (IPO), has announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer. The IPO proceeds will primarily support the Phase III clinical trial of its schizophrenia drug.

Panandiker has extensive experience in the commercialization of central nervous system drugs. She led the U.S. launches of the antidepressants Rexulti and Trintellix, as well as the long-acting injectable formulation of aripiprazole for bipolar disorder, during her time at Lundbeck. Later, she served as the Head of Business Development at Cerevel Therapeutics and as Chief Commercial Officer at Neumora Therapeutics. Notably, after AbbVie acquired Cerevel at the end of 2023, she moved to Neumora but left earlier this year after only 13 months due to the failure of a Phase III trial for the company’s depression drug, which caused a sharp drop in its stock price.

LB Pharma Admits in IPO Filing That It Has Yet to Establish a Commercial Operation System; Panandiker’s Arrival Marks the Crucial First Step in Building Internal Commercialization Capabilities. This Appointment Continues Her Career Trajectory of "Stepping In During Critical Moments," Joining Pharmaceutical Companies at Pivotal Stages Before New Drug Launches.

Celldex Therapeutics Changes Leadership to Focus on Commercialization of New Dermatology Drugs

On the other hand, Celldex Therapeutics has also completed the transition of its business leadership. Following the retirement of former Chief Business Officer Richard Wright, Teri Lawver has taken the helm to lead the company's commercialization strategy.

Lawver has 20 years of experience at Johnson & Johnson, during which she was deeply involved in the commercialization processes of several blockbuster biologics such as Remicade, Stelara, and Tremfya. In early 2023, she left Johnson & Johnson to join medical technology giant Dexcom as Chief Commercial Officer, gaining cross-disciplinary business management experience.

Celldex’s Recent Leadership Change Focuses on Core Asset —— Barzolvolimab for Dermatological Conditions. The drug is currently in the final stages of Phase III clinical trials. In fact, this is not the first time Celldex has structured a commercial team in preparation for a new drug launch: In 2015, the company appointed Wright as Chief Commercial Officer (CCO) to prepare for the launch of the cancer vaccine Rintega, but the drug failed in its Phase III trial in 2016, and Wright has remained in his position ever since.

The company said in February this year that its current commercial capabilities are focused on providing market insights for the R&D team, but it did not rule out the possibility of building a full launch team for barzolvolimab. Since then, Celldex has significantly increased its spending related to commercial planning, paving the way for the new drug's market entry.

Commercialization Layout Becomes the Core of Pharmaceutical Companies' Competition

Two pharmaceutical companies have almost simultaneously bolstered their commercial teams, reflecting a shift in the competitive logic of the biopharmaceutical industry. For innovative drug companies, the final stage of Phase III clinical trials represents the "golden window period" for commercialization planning. The early involvement of senior commercial executives can help enterprises accurately grasp market demands, establish sales channels, and shorten the time from drug approval to scaling up.

Panandiker's experience in launching central nervous system drugs aligns closely with LB Pharma's pipeline of psychiatric medications; meanwhile, Lawver's commercial expertise in autoimmune diseases perfectly matches the development direction of barzolvolimab. This "precise talent acquisition" reflects pharmaceutical companies' pursuit of maximum commercial efficiency and signals upcoming market competition in the fields of schizophrenia and dermatological treatments.

Reference Source:https://www.fiercepharma.com/marketing/lb-and-celldex-hire-commercial-chiefs-launch-plans-ramp

Scan the WeChat QR code, add the editor of the Biological Products Circle, and those who meet the requirements can join.
Biological Products WeChat Group!
Please indicate: Name + Research Direction!

Edition
Authority
Sound
Ming

All articles reproduced in this official account are intended to convey more information, with the source and author clearly indicated. Media or individuals who do not wish to be reprinted may contact us (cbplib@163.com), and we will immediately proceed with deletion. All articles represent the views of the author and not of this site.